2018
DOI: 10.3390/v10120699
|View full text |Cite
|
Sign up to set email alerts
|

Chaperoning the Mononegavirales: Current Knowledge and Future Directions

Abstract: The order Mononegavirales harbors numerous viruses of significant relevance to human health, including both established and emerging infections. Currently, vaccines are only available for a small subset of these viruses, and antiviral therapies remain limited. Being obligate cellular parasites, viruses must utilize the cellular machinery for their replication and spread. Therefore, targeting cellular pathways used by viruses can provide novel therapeutic approaches. One of the key challenges confronted by both… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
13
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
3
2
1

Relationship

1
5

Authors

Journals

citations
Cited by 12 publications
(15 citation statements)
references
References 125 publications
(250 reference statements)
2
13
0
Order By: Relevance
“…Not surprisingly, observations of several such drug effects are not easily extrapolatable to in vivo data 152 , 153 . The likelihood of finding a lyssavirus-specific modality is predictably low, compared to the potential finesse of broader approaches for other “high-stakes” RNA virus targets among the Mononegavirales 154 . In the interim, this highly controversial aspect of the field will see-saw between an empirical, research-based in vitro / in vivo side and an emergency “hit-or-miss best guess” slant to clinical treatment of lyssavirus encephalitis, in which, among others, patient families, hospital administrators, multiple medical specialties, national regulators, ethicists, viral diagnosticians, and developers of novel biologics, as well as fit-for-purpose anti-viral drugs, will all play a part 2 , 42 , 55 , 150 155 .…”
Section: Experimental Treatment Optionsmentioning
confidence: 99%
“…Not surprisingly, observations of several such drug effects are not easily extrapolatable to in vivo data 152 , 153 . The likelihood of finding a lyssavirus-specific modality is predictably low, compared to the potential finesse of broader approaches for other “high-stakes” RNA virus targets among the Mononegavirales 154 . In the interim, this highly controversial aspect of the field will see-saw between an empirical, research-based in vitro / in vivo side and an emergency “hit-or-miss best guess” slant to clinical treatment of lyssavirus encephalitis, in which, among others, patient families, hospital administrators, multiple medical specialties, national regulators, ethicists, viral diagnosticians, and developers of novel biologics, as well as fit-for-purpose anti-viral drugs, will all play a part 2 , 42 , 55 , 150 155 .…”
Section: Experimental Treatment Optionsmentioning
confidence: 99%
“…Upon independent expression in mammalian cells, NP forms cytoplasmic inclusion bodies, where it has been shown to interact with host RNA (Noda et al, 2010;Emanuel et al, 2018). L is a multidomain enzymatic component of the system, responsible for transcription, replication, genome capping, and polyadenylation (Latorre et al, 2018). Lastly, P/ VP35 serve as a cofactor by linking the L and NP proteins (P in paramyxoviruses and VP35 in filoviruses).…”
Section: Virus Replicationmentioning
confidence: 99%
“…Lastly, P/ VP35 serve as a cofactor by linking the L and NP proteins (P in paramyxoviruses and VP35 in filoviruses). Moreover, it has been proposed that P/VP35 carry out chaperone functions by obstructing the self-association of NP and nonproductive associations between NP and RNA, allowing replication to complete before NP begins its helical assembly around the viral genome (Latorre et al, 2018). When expressed together, NP, P/VP35, and L colocalize in the cell and fulfill each requirement for productive viral transcription and replication.…”
Section: Virus Replicationmentioning
confidence: 99%
See 2 more Smart Citations